Development of inhaled moxifloxacin-metformin formulation as an alternative for pulmonary tuberculosis treatment
Authors:
- 26 September 2024
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 666, 124740
Abstract
No abstract availableKeywords
Funding Information
- Oswaldo Cruz Foundation
- European Regional Development Fund
This publication has 122 references indexed in Scilit:
- Evaluation of the Compatibility of Moxifloxacin with Selected Excipients Used in the Formulation of NanopharmaceuticalsPharmaceutical Chemistry Journal, 2022
- Evaluation of spironolactone compatibility with magnesium stearate and other lubricants in paediatric formulation using thermal and nonthermal techniquesJournal of Thermal Analysis and Calorimetry, 2021
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018JAMA, 2020
- In Vitro Models for Studying Transport Across Epithelial Tissue BarriersAnnals of Biomedical Engineering, 2018
- A Review of Moxifloxacin for the Treatment of Drug‐Susceptible TuberculosisThe Journal of Clinical Pharmacology, 2017
- Drug Transporter Protein Quantification of Immortalized Human Lung Cell Lines Derived from Tracheobronchial Epithelial Cells (Calu-3 and BEAS2-B), Bronchiolar–Alveolar Cells (NCI-H292 and NCI-H441), and Alveolar Type II-like Cells (A549) by Liquid Chromatography–Tandem Mass SpectrometryJournal of Pharmaceutical Sciences, 2015
- Detection of Cocrystal Formation Based on Binary Phase Diagrams Using Thermal AnalysisPharmaceutical Research, 2012
- Compatibility studies of aceclofenac with retard tablet excipients by means of thermal and FT-IR spectroscopic methodsJournal of Thermal Analysis and Calorimetry, 2010
- Pharmaceutical Particle Engineering via Spray DryingPharmaceutical Research, 2007
- Particle Size and Density in Spray Drying—Effects of Carbohydrate PropertiesJournal of Pharmaceutical Sciences, 2005